Hancock Whitney’s Acceleron Pharma XLRN Stock Holding History

Hancock Whitney’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,334	Closed	-$210K	–	897
2020 Q1	$210K	Buy	+2,334	New	+$181K	0.01%	726

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Hancock Whitney's XLRN Position: Q2 2020 in Review

Hancock Whitney sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 2,334 shares — an estimated $210K sold.

Hancock Whitney first reported a position in XLRN in Q1 2020 and held it in 1 quarter. The position peaked at $210K in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

Hancock Whitney reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
Hancock Whitney sold 2,334 Acceleron Pharma shares in Q2 2020, an estimated $210K.
Hancock Whitney first reported a position in Acceleron Pharma in Q1 2020 and held it in 1 quarter.
Hancock Whitney's Acceleron Pharma position peaked at $210K in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Hancock Whitney's 13F filing for Q2 2020, filed 30 Jul 2020.